Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 09, 2024, titled "Zydus Announces Completion of Enrolment for EPICS IIITM Phase 2b/3 trial evaluating Saroglitazar Mg in treatment of Primary Biliary Cholangitis".